Corticosteroids for Cancer Pain

Inclusion Criteria: * Verified malignant disease * Receiving a scheduled strong or weak opioid * Insufficient pain control: Average pain last 24 h: ≥ 4 (NRS 0-10) * Given informed consent according to the ethical guidelines * Able to complete planned assessment schedules * ≥ 18 years of age * Life expectancy \> 1 month Exclusion Criteria: * Excruciating pain (average pain ≥ 8) (These patients should be considered as emergency patients. Patients may be eligible for the study after stabilization) * Dose adjustment in scheduled opioid medication last 48 hours * Concurrent medication with NSAIDs (Patients are eligible for the study one week after NSAIDs are discontinued) * Receiving radiotherapy within 4 weeks before entering the study or planned within the study period * Started systemic treatment (chemotherapy, hormone therapy or bisphosphonates) within 4 weeks before entering the study Patients who have received chemotherapy for more than 4 weeks are eligible for the study if it is more than 7 days since receiving the last dose and they are not having the next dose within the study period * Manifest spinal cord compression or in need of bone surgery * Severe cognitive impairment * Previously on steroids during the last 4 weeks * Diabetes mellitus * Known peptic ulcer disease * Systemic fungal disease, patients vaccinated with viable viruses, and patients with known allergies to the study medication (MethylPrednisolone) * Female patients who are pregnant or lactating. * Women of reproductive potential not willing or unable to employ an effective method of contraception (be sterilized, using IUD or oral contraception) * Patients using following medication: cyclosporin, erythromycin, phenobarbital, phenytoin, carbamazepin, ketoconazole, methotrexate, ciclofosfamide, rifampicin, aprepitant and diltiazem.